Deep knowledge on 
 small-molecule drugs and 
 the 110,000 global patents 
 covering them 

Free Patent Expiration Alerts


Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

RANEXA Drug Profile

« Back to Dashboard
Ranexa is a drug marketed by Gilead and is included in one NDA. It is available from three suppliers. There are ten patents protecting this drug.

This drug has ninety-two patent family members in twenty-nine countries.

The generic ingredient in RANEXA is ranolazine. There are twelve drug master file entries for this compound. Three suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the ranolazine profile page.

Summary for Tradename: RANEXA

Patents:10
Applicants:1
NDAs:1
Suppliers / Packagers: see list3

Clinical Trials for: RANEXA

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-001Feb 12, 2007RXYes6,303,607<disabled> <disabled>
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-002Jan 27, 2006RXNo6,617,328<disabled>Y <disabled>
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-001Feb 12, 2007RXYes6,864,258<disabled> <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: RANEXA

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-002Jan 27, 20064,567,264<disabled>
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-001Feb 12, 20074,567,264<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: RANEXA

Country Document Number Estimated Expiration
Turkey200101261<disabled in preview>
Australia2008212005<disabled in preview>
Australia6142599<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: RANEXA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1Finland<disabled>
C0001France<disabled>PRODUCT NAME: RANOLAZINE OU L?UN DE SES SELS OU L?UN DE SES SOLVATES; REGISTRATION NO/DATE IN FRANCE: EU/1/08/462/001 DU 20080709; REGISTRATION NO/DATE AT EEC: EU/1/08/462/001-006 DU 20080709
2008 00051Denmark<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Connect with Social Media:

`abc